Filing Flows › Macrogenics (MGNX) › Q1 2026 › vs Q1 2025
Macrogenics (MGNX) Q1 2026 vs Q1 2025 (year over year)
Macrogenics's revenue rose $7.6M (+57%) from $13.2M in Q1 2025 to $20.8M in Q1 2026. The biggest changes: Contract manufacturing +$7.9M (+129%); Collaborative and other agreements −$6.0M (-91%); Royalty revenue +$5.8M (15×).
Macrogenics, Q1 2026: revenue $20.8M (+58% year over year), operating margin -161.0%, net loss $36.8M, operating cash flow −$35.8M. The chart draws each line against Q1 2025, the increases inside each band.
Every line
| Line | Q1 2026 | Q1 2025 | Change | % |
|---|---|---|---|---|
| Contract manufacturing | $14.1M | $6.2M | $7.9M | +129% |
| Royalty revenue | $6.2M | $400K | $5.8M | 15× |
| Collaborative and other agreements | $570K | $6.6M | −$6.0M | -91% |
| Revenue | $20.8M | $13.2M | $7.6M | +57% |
| Net loss | $36.8M | $41.0M | −$4.3M | -10% |
| Costs & expenses | $57.5M | $55.8M | $1.7M | +3% |
| Operating costs | $54.2M | $55.8M | −$1.6M | -3% |
| Interest & other, net | $3.3M | −$1.6M | $4.9M | — |
| Research & development | $35.0M | $39.7M | −$4.7M | -12% |
| General & admin | $9.7M | $10.7M | −$1.0M | -9% |
| Other operating costs | $9.5M | $5.4M | $4.1M | +76% |
| Operating cash sources | $40.1M | $53.0M | −$12.9M | -24% |
| Depreciation & amortization | $1.7M | $1.8M | −$84K | -5% |
| Share-based compensation | $2.6M | $4.4M | −$1.7M | -40% |
| Cash used in operations | $35.8M | $46.9M | −$11.1M | -24% |
| Net loss absorbed | $36.8M | $41.0M | −$4.3M | -10% |
| Working capital & other | $3.4M | $12.0M | −$8.6M | -72% |
Questions
How much did Macrogenics's revenue grow year over year in Q1 2026?
Macrogenics's revenue rose $7.6M (+57%) from $13.2M in Q1 2025 to $20.8M in Q1 2026.
What drove Macrogenics's revenue change in Q1 2026?
Contract manufacturing +$7.9M (+129%); Collaborative and other agreements −$6.0M (-91%); Royalty revenue +$5.8M (15×).